{"id":70782,"date":"2026-07-28T18:10:39","date_gmt":"2026-07-28T10:10:39","guid":{"rendered":"https:\/\/flcube.com\/?p=70782"},"modified":"2026-07-28T18:10:40","modified_gmt":"2026-07-28T10:10:40","slug":"sichuan-keluns-dual-payload-adc-skb565-receives-nmpa-clearance-for-advanced-solid-tumor-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70782","title":{"rendered":"Sichuan Kelun&#8217;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Kelun Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002422:SHE\">SHE: 002422<\/a>) announced that <strong>SKB565<\/strong>, a <strong>dual-payload antibody-drug conjugate (ADC)<\/strong>, has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate clinical trials for the treatment of <strong>advanced solid tumors<\/strong>. The investigational therapy was developed using the proprietary <strong>OptiDC platform<\/strong> from Kelun&#8217;s subsidiary, <strong>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/strong> (&#8220;Kelun-Biotech&#8221;).<\/p>\n\n\n\n<h2 id=\"h-development-overview\" class=\"wp-block-heading\">Development Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary OptiDC platform<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Dual-payload Antibody-Drug Conjugate (ADC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>28 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> SKB565<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class <strong>dual-payload design<\/strong> delivering two distinct therapeutic agents simultaneously<\/li>\n\n\n\n<li><strong>Payload Components:<\/strong><\/li>\n\n\n\n<li><strong>Toxin:<\/strong> Cytotoxic agent for direct tumor cell killing<\/li>\n\n\n\n<li><strong>Immunomodulator:<\/strong> Immune system activator to enhance antitumor response<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Synergistic action through targeted delivery of both payloads directly to tumor tissues, maximizing efficacy while minimizing systemic toxicity<\/li>\n\n\n\n<li><strong>Platform Advantage:<\/strong> OptiDC platform enables precise payload ratio control and optimized linker stability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Antitumor Activity<\/strong><\/td><td>Excellent in multiple solid tumor models<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable with manageable toxicity<\/td><\/tr><tr><td><strong>Therapeutic Index<\/strong><\/td><td>Enhanced compared to single-payload ADCs<\/td><\/tr><tr><td><strong>Target Specificity<\/strong><\/td><td>High tumor tissue selectivity demonstrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Preclinical studies have demonstrated that SKB565&#8217;s innovative dual-payload approach achieves superior antitumor activity compared to conventional single-payload ADCs, while maintaining a favorable safety profile suitable for clinical development.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China ADC Landscape:<\/strong> Represents another significant advancement in China&#8217;s rapidly growing ADC pipeline, positioning Kelun as a key player in next-generation targeted therapies<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Dual-payload approach addresses limitations of current ADCs by combining direct cytotoxic effects with immune system activation<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Successful clinical development could position SKB565 for international partnerships and regulatory filings beyond China<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Clinical success would validate Kelun-Biotech&#8217;s OptiDC platform for future dual-payload candidates across multiple indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for SKB565. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u79d1\u4f26\u836f\u4e1a\uff1a\u5173\u4e8e\u5b50\u516c\u53f8SKB565\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u79d1\u4f26\u836f\u4e1a\uff1a\u5173\u4e8e\u5b50\u516c\u53f8SKB565\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-25f30b09-c800-468f-82d6-dc1504cf1be7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u79d1\u4f26\u836f\u4e1a\uff1a\u5173\u4e8e\u5b50\u516c\u53f8SKB565\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u516c\u544a.pdf\">\u79d1\u4f26\u836f\u4e1a\uff1a\u5173\u4e8e\u5b50\u516c\u53f8SKB565\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u79d1\u4f26\u836f\u4e1a\uff1a\u5173\u4e8e\u5b50\u516c\u53f8SKB565\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-25f30b09-c800-468f-82d6-dc1504cf1be7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,62,371,1185],"class_list":["post-70782","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-kelun-pharmaceutical","tag-she-002422"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Kelun&#039;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun&#039;s subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (&quot;Kelun-Biotech&quot;).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70782\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Kelun&#039;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun&#039;s subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (&quot;Kelun-Biotech&quot;).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70782\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T10:10:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T10:10:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70782#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70782\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Kelun&#8217;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials\",\"datePublished\":\"2026-07-28T10:10:39+00:00\",\"dateModified\":\"2026-07-28T10:10:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70782\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"Kelun Pharmaceutical\",\"SHE: 002422\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70782#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70782\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70782\",\"name\":\"Sichuan Kelun's Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-28T10:10:39+00:00\",\"dateModified\":\"2026-07-28T10:10:40+00:00\",\"description\":\"Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun's subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\\\"Kelun-Biotech\\\").\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70782#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70782\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70782#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Kelun&#8217;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Kelun's Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun's subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\"Kelun-Biotech\").","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70782","og_locale":"en_US","og_type":"article","og_title":"Sichuan Kelun's Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials","og_description":"Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun's subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\"Kelun-Biotech\").","og_url":"https:\/\/flcube.com\/?p=70782","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-28T10:10:39+00:00","article_modified_time":"2026-07-28T10:10:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70782#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70782"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Kelun&#8217;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials","datePublished":"2026-07-28T10:10:39+00:00","dateModified":"2026-07-28T10:10:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70782"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","Kelun Pharmaceutical","SHE: 002422"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70782#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70782","url":"https:\/\/flcube.com\/?p=70782","name":"Sichuan Kelun's Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-28T10:10:39+00:00","dateModified":"2026-07-28T10:10:40+00:00","description":"Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun's subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\"Kelun-Biotech\").","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70782#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70782"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70782#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Kelun&#8217;s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70782"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70782\/revisions"}],"predecessor-version":[{"id":70784,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70782\/revisions\/70784"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}